H0RSHOLM, Denmark--(BUSINESS WIRE)--LifeCycle Pharma A/S (OMX: LCP) (the “Company” or “LCP”), an emerging specialty pharmaceutical company, today announced that it has initiated a Phase II clinical trial for LCP-Tacro, an immunosuppressant to prevent organ rejection in liver transplant recipients. The clinical trial is expected to enroll up to 50 patients in up to 12 centers throughout the U.S. The Company expects to report clinical trial results in the first half of 2008 (1H08).
